Clinical and pathologic predictors of complete pathologic response to neoadjuvant docetaxel/anthracycline chemotherapy in breast cancer patients

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 836-836 ◽  
Author(s):  
M. Coplin ◽  
M. Naughton
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Pathologic Response ◽  
Complete Pathologic Response ◽  
Breast Cancer Patients ◽  
Anthracycline Chemotherapy

scholarly journals Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 502-502 ◽  
Author(s):  
J. Gronwald ◽  
T. Byrski ◽  
T. Huzarski ◽  
R. Dent ◽  
V. Bielicka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Neoadjuvant Therapy ◽  
Cancer Patients ◽  
Brca1 Mutation ◽  
Complete Response ◽  
Pathologic Response ◽  
Complete Pathologic Response ◽  
Breast Cancer Patients ◽  
Platinum Based Chemotherapy

502 Background: Neoadjuvant chemotherapy is administered to control disease, make surgical resection possible and increase the possibility of breast tissue conservation. A further advantage of neoadjuvant therapy is that it helps to assess chemo-sensitivity to a particular agent. Induction of a pathological complete response (pCR) is one of the primary goals of neoadjuvant therapy in order to achieve a better disease-free and overall survival. Experimental data suggest that BRCA1 related breast cancer may have increased sensitivity to platinum-based chemotherapy, but clinical data are limited. The aim of this study was to evaluate the frequency of complete pathologic response after neo-adjuvant treatment with cisplatin chemotherapy in women with breast cancer and a BRCA1 mutation. Methods: Twenty five women with breast cancer and a BRCA1 mutation with stage I, II, and III breast cancer between December 2006 and December 2008 were entered into this study. Patients were treated with cisplatin 75 mg/m2 intravenously every three weeks for four cycles. After chemotherapy, patients underwent surgery and were assessed for pathologic response in both the breast and axillary lymph nodes. Complete pathologic response was defined as no residual invasive disease in both the breast and axilla, however ductal carcinoma in situ was allowed. Results: Twenty five patients were enrolled in the study. Thirteen patients had tumors of greater than two centimeters (52%) and seven patients had positive lymph nodes at diagnosis (28%). Twenty two patients completed four cycles of cisplatin (88%) and three patients completed two cycles (12%). Clinical complete response was observed in eighteen patients (72%). Pathologic complete response was observed in eighteen patients (72%). Conclusions: Platinum-based chemotherapy is effective in a high proportion of patients with BRCA1-associated breast cancers. Clinical trials are warranted to determine the optimum treatment for this subgroup of breast cancer patients. No significant financial relationships to disclose.

Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients

The Breast ◽  
2018 ◽  
Vol 39 ◽  
pp. 19-23 ◽  
Author(s):  
Annina Baumgartner ◽  
Christoph Tausch ◽  
Stefanie Hosch ◽  
Bärbel Papassotiropoulos ◽  
Zsuzsanna Varga ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Pathologic Response ◽  
Breast Cancer Patients ◽  
Response To Neoadjuvant Chemotherapy

scholarly journals Determinants of exercise intolerance in breast cancer patients prior to anthracycline chemotherapy

2019 ◽  
Vol 7 (1) ◽  
pp. e13971 ◽  
Author(s):  
Rhys I. Beaudry ◽  
Erin J. Howden ◽  
Steve Foulkes ◽  
Ashley Bigaran ◽  
Piet Claus ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Exercise Intolerance ◽  
Breast Cancer Patients ◽  
Anthracycline Chemotherapy

scholarly journals Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients from Southern Sri Lanka: An Echocardiographic Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Jayasinghe Arachchige Nirosha Sandamali ◽  
Ruwani Punyakanthi Hewawasam ◽  
Madappuli Arachchige Chaminda Sri Sampath Fernando ◽  
Kamani Ayoma Perera Wijewardana Jayatilaka ◽  
Ranji Duleep Madurawe ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Left Ventricular ◽  
Breast Cancer Patients ◽  
Anthracycline Therapy ◽  
Echocardiographic Parameters ◽  
Chemotherapy Dose ◽  
Anthracycline Dose ◽  
Anthracycline Chemotherapy

Anthracycline-induced cardiotoxicity has never been investigated in Sri Lanka. Therefore, this study was conducted to determine the prevalence of anthracycline-induced cardiotoxicity in breast cancer patients using echocardiographic findings. A prospective cohort study was performed. All newly diagnosed breast cancer patients who were administered with anthracycline and cyclophosphamide (AC schedule) for the first time were enrolled in the study. In the hospital setting, anthracycline is administered only as a combination therapy, and only this combination was selected to limit the effect of other cardiotoxic chemotherapy agents. Records of echocardiography were obtained: one day before anthracycline chemotherapy (baseline), one day after the first chemotherapy dose, one day after the last chemotherapy dose, and six months after the completion of anthracycline chemotherapy. Following parameters were recorded from the echocardiography results: ejection fraction (EF, %), fractioning shortening (FS, %), posterior wall thickness, left ventricle (PWT, mm), the thickness of interventricular septum (IVS, mm), left ventricular end-diastolic diameter (LVEDD, mm), and left ventricular end-systolic diameter (LVESD, mm). Statistical analysis of the echocardiography results was performed using ANOVA at four stages. A p value <0.05 was considered significant. Subclinical cardiac dysfunction was defined as a fall of EF >10% during the follow-up echocardiography. There was no significant change ( p > 0.05 ) between the baseline echocardiographic parameters and one day after the 1st anthracycline dose. However, significant differences ( p < 0.05 ) were observed between the baseline echocardiographic parameters and one day after the last anthracycline dose and six months after the completion of anthracycline therapy with a gradual and progressive deterioration in functional parameters including EF, FS, PWT, and IVS over time. There were 65 patients out of 196 (33.16%) who developed subclinical cardiac dysfunction six months after the completion of anthracycline chemotherapy. The prevalence of subclinical anthracycline-induced cardiotoxicity was relatively higher in these patients. An equation was also developed based on left ventricular ejection fraction (LVEF) to predict the anthracycline-induced cardiotoxicity of a patient six months after the completion of anthracycline chemotherapy. We believe that this will help in the monitoring of patients who undergo anthracycline therapy for cardiotoxicity. It is recommended to carry out a long-term follow-up to detect early-onset chronic progressive cardiotoxicity in all patients who were treated with anthracycline therapy.

scholarly journals Aquaporin 1 promotes sensitivity of anthracycline chemotherapy in breast cancer by inhibiting β-catenin degradation to enhance TopoIIα activity

2020 ◽  
Vol 28 (1) ◽  
pp. 382-400
Author(s):  
Wei Chong ◽  
Huikun Zhang ◽  
Zhifang Guo ◽  
Limin Yang ◽  
Ying Shao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Nuclear Translocation ◽  
Glycogen Synthase ◽  
Breast Cancer Mortality ◽  
High Sensitivity ◽  
Breast Cancer Patients ◽  
Chemotherapy Drugs ◽  
Aqp1 Expression ◽  
Anthracycline Chemotherapy

AbstractAnthracyclines are a class of conventional and commonly used frontline chemotherapy drugs to treat breast cancer. However, the anthracycline-based regimens can only reduce breast cancer mortality by 20–30%. Furthermore, there is no appropriate biomarker for predicting responses to this kind of chemotherapy currently. Here we report our findings that may fill this gap by showing the AQP1 (Aquaporin1) protein as a potential response predictor in the anthracycline chemotherapy. We showed that breast cancer patients with a high level of AQP1 expression who underwent the anthracycline treatment had a better clinical outcome relative to those with a low level of AQP1 expression. In the exploration of the underlying mechanisms, we found that the AQP1 and glycogen synthase kinase-3β (GSK3β) competitively interacted with the 12 armadillo repeats of β-catenin, followed by the inhibition of the β-catenin degradation that led to β-catenin’s accumulation in the cytoplasm and nuclear translocation. The nuclear β-catenin interacted with TopoIIα and enhanced TopoIIα’s activity, which resulted in a high sensitivity of breast cancer cells to anthracyclines. We also found, the miR-320a-3p can attenuate the anthracycline’s chemosensitivity by inhibiting the AQP1 expression. Taken together, our findings suggest the efficacy of AQP1 as a response predictor in the anthracycline chemotherapy. The application of our study includes, but is not limited to, facilitating screening of the most appropriate breast cancer patients (who have a high AQP1 expression) for better anthracycline chemotherapy and improved prognosis purposes.

Sign in / Sign up

Export Citation Format

Share Document